VivoSeq
Other

T Cells

0

Pipeline Programs

25

Active Trials

4

Companies Involved

T Cells is an early-stage landscape with 0 programs across 4 companies. The most active players are Hrain Biotechnology Co., Ltd., CARsgen Therapeutics Co., Ltd., Bioceltech Therapeutics, Ltd..

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

56/100

Attrition Rate

17/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

63

clinical trials

Recruiting15 · 24%
Completed14 · 22%
Unknown status12 · 19%
Terminated8 · 13%
Active, not recruiting7 · 11%
Withdrawn3 · 5%
Other4 · 6%

Trial Activity

63 trials

CAR T Cells to Target GD2 for DMG
Recruiting·UUniversity College, London·Phase 1·NCT05544526·12 enrolled
A Multicenter Study of CAR-T Cells in Primary Ph+All
Recruiting·ZZhejiang University·Phase 2·NCT07252336·50 enrolled
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
Recruiting··Phase 1·NCT06445803·48 enrolled
MOv19-BBz CAR T Cells in FRa+ Cancers
Recruiting·UUniversity of Pennsylvania·Phase 1·NCT07116057·10 enrolled
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
Recruiting··Phase 1/2·NCT06839976·24 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)